Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
ID:
Password:
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

Agents/Distributors
 Regional Subscription Agents/Distributors
 
Current Trends in Endocrinology   Volumes    Volume 7 
Abstract
Discontinuation of dopamine agonists after treatment of prolactinoma
Bernard Corenblum
Pages: 95 - 98
Number of pages: 4
Current Trends in Endocrinology
Volume 7 

Copyright © 2014 Research Trends. All rights reserved

ABSTRACT
 
After years of successful therapy for pathological hyperprolactinemia with dopamine agonists, an attempt of drug withdrawal could be undertaken in selected clinically stable patients. Either long-term remission or relapse of disease may occur. Disease relapse should be defined as hyperprolactinemia with return of clinical symptoms, not just the biochemical marker itself. With this definition in 168 patients, 37% of the bromocriptine group and 22% of the cabergoline group did have a biochemical and clinical relapse and were re-administered the dopamine agonist. The remainder were clinically asymptomatic, despite return of hyperprolactinemia in some, but they did not require further therapy. An asymptomatic increase of serum prolactin does not change the clinical state of remission.
Buy this Article


 
search


E-Commerce
Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Login
Search Products
Browse in Alphabetical Order : Journals
Series/Books
Browse by Subject Classification : Journals
Series/Books

Miscellaneous
Ordering Information Ordering Information
Downloadable forms Downloadable Forms